Cidara Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	1.28	23.28	23.5	49.57	12.07	Upgrade
Revenue Growth (YoY)	-94.52%	-0.91%	-52.60%	310.81%	-42.30%	Upgrade
Cost of Revenue	71.88	36.76	30.17	73.09	68.02	Upgrade
Gross Profit	-70.6	-13.48	-6.67	-23.52	-55.95	Upgrade
Selling, General & Admin	20.62	13.58	15.23	18.74	15.9	Upgrade
Operating Expenses	20.62	13.58	15.23	18.74	15.9	Upgrade
Operating Income	-91.22	-27.06	-21.9	-42.26	-71.85	Upgrade
Interest Expense	-	-	-	-0.21	-0.26	Upgrade
Interest & Investment Income	5.81	2	0.19	-	-	Upgrade
EBT Excluding Unusual Items	-85.41	-25.07	-21.71	-42.47	-72.11	Upgrade
Pretax Income	-170.29	-25.07	-21.71	-42.47	-72.11	Upgrade
Income Tax Expense	-	0.02	0.01	-	-	Upgrade
Earnings From Continuing Operations	-170.29	-25.08	-21.72	-42.47	-72.11	Upgrade
Earnings From Discontinued Operations	0.46	2.15	-11.86	-	-	Upgrade
Net Income	-169.83	-22.93	-33.58	-42.47	-72.11	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	-	2.76	Upgrade
Net Income to Common	-169.83	-22.93	-33.58	-42.47	-74.87	Upgrade
Shares Outstanding (Basic)	6	4	3	3	2	Upgrade
Shares Outstanding (Diluted)	6	4	3	3	2	Upgrade
Shares Change (YoY)	45.26%	25.15%	33.18%	26.22%	38.83%	Upgrade
EPS (Basic)	-26.75	-5.25	-9.61	-16.19	-36.03	Upgrade
EPS (Diluted)	-26.75	-5.25	-9.61	-16.20	-36.03	Upgrade
Free Cash Flow	-176.66	-22.94	-28.59	-25.27	-54.6	Upgrade
Free Cash Flow Per Share	-27.82	-5.25	-8.19	-9.64	-26.27	Upgrade
Gross Margin	-	-57.90%	-28.40%	-47.44%	-	Upgrade
Operating Margin	-7154.43%	-116.22%	-93.20%	-85.24%	-595.42%	Upgrade
Profit Margin	-13319.77%	-98.49%	-142.94%	-85.67%	-620.48%	Upgrade
Free Cash Flow Margin	-13855.84%	-98.51%	-121.69%	-50.98%	-452.45%	Upgrade
EBITDA	-91.07	-26.95	-21.76	-42.07	-71.56	Upgrade
EBITDA Margin	-	-115.74%	-92.59%	-84.86%	-	Upgrade
D&A For EBITDA	0.15	0.11	0.14	0.19	0.29	Upgrade
EBIT	-91.22	-27.06	-21.9	-42.26	-71.85	Upgrade
EBIT Margin	-	-116.22%	-93.20%	-85.24%	-	Upgrade
Revenue as Reported	1.28	23.28	23.5	49.57	12.07	Upgrade

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q